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Abstract
Background: The efficacy of dual-chamber cardiac pacing in neuro-mediated reflex syncope with a cardio-inhibitory
response to the Tilt-Table test (TT) has not been definitively assessed so far. The lack of reproducibility of results from
previous studies may be partially explained by discrepancies in subject selection and some weaknesses in design and
methods. The European Society of Cardiology (ESC) has set a class IIb indication to pacemaker implantation in this
population recommending further research.
Methods/design: The BIOSync study is a multicenter, patient- and outcome-assessor-blind, randomized, parallel-arm,
placebo-controlled trial with the objective of assessing the clinical benefit of cardiac pacing in patients with frequently
recurrent reflex syncope, suspected (but not proven) to be triggered by asystolic pauses as showing a VASIS 2B response
to the TT (>3-s pause regardless of blood pressure drop). The primary and secondary endpoints are time to first
post-implantation recurrence of syncope or the combination of pre-syncope or syncope, respectively. One hundred
and twenty-eight consenting patients will be 1:1 randomized to dual-chamber cardiac pacing ‘on’ or ‘off’ after
pacemaker implantation, and followed up until the first adjudicated primary endpoint event for a maximum of 2
years. The so-called Closed Loop Stimulation function on top of dual-chamber pacing is the pacing mode selected in
the study active arm. Participating patients are asked to self-report syncopal symptoms at least every 3 months with
self-administered questionnaires addressed to an independent Adjudication Committee. Patients and members of the
Adjudicating Committee are blinded to randomization. The study is designed to detect a 40% relative reduction in the
2-year incidence of syncopal recurrences with 80% statistical power.
Discussion: The BIOSync study is designed to definitively assess the benefit of pacing against placebo in reflex syncope
patients with a cardio-inhibitory response to the TT. The study will also provide important information on the efficiency of
the TT in appropriately selecting reflex syncope patients for cardiac pacing.
Trial registration: ClinicalTrials.gov, identifier: NCT02324920 (27 October 2016, date last accessed).
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Background
The latest update of the European Society of Cardiology
(ESC) guidelines has set a class IIb indication with level
of evidence B for permanent cardiac pacing in patients
aged 40 years or older with a cardio-inhibitory response
to the Tilt-Table test (TT) and recurrent, frequent, unpre-
dictable syncope after alternative therapy has failed [1].
The indication is based on randomized clinical trials
which could not lead to conclusive evidence due to the
lack of reproducible results only partially explained by
intrinsic limitations in study design [2–8].
Current knowledge about the effect of pacing in reflex
syncope is still characterized by at least two points need-
ing further evaluation: (1) whether selecting patients who
are prone to TT-specific orthostatic stress is sufficiently
efficient in identifying ideal candidates for cardiac pacing,
(2) definitively clarifying whether or not the benefits of
pacing justify related implications in this class of patients.
This probably explains why the ESC Task Force for
cardiac pacing considers further research to be extremely
important and very likely to impact future recommenda-
tions [1]. We believe that the methods and design of the
study protocol here presented (version n. 7.0, 20 June 2016)
will challenge the current uncertainty related to the class
IIb indication by providing clearer evidence either in favor
of, or against, cardiac pacing.
Methods/design
Purpose and study design
The BIOSync study (ClinicalTrials.gov, identifier:
NCT02324920; Eudamed number: CIV-05-013546) is
a multicenter, patient- and outcome-assessor-blind,
randomized, parallel-arm, placebo-controlled trial with the
objective of assessing the clinical benefit of cardiac pacing
in patients with frequently recurrent reflex syncope, sus-
pected (but not proven) to be triggered by asystolic pauses
as showing a VAsovagal Syncope International Study
(VASIS) 2B response to the TT (>3-s pause regardless
of pressure drop [9]).
The study is sponsored by BIOTRONIK SE & Co. KG
(Berlin, Germany) and is being conducted in accordance
with the principles outlined in the Declaration of
Helsinki and in compliance with the ISO 14155 Good
Clinical Practice (GCP) standards for clinical studies on
pre-market medical devices. Thirty sites are planned to be
recruited in Italy, France, Spain, Portugal, Netherlands and
Canada where Ethics Committee approvals have been ob-
tained or application is currently under evaluation or prep-
aration (please refer to Additional file 1 for a complete list
of Ethics Committee approvals and applications). Despite
all the investigational devices (BIOTRONIK Eluna 8 DR-T
family) normally available on the market, pacemaker pro-
gramming required by the protocol in the control study
arm (pacing ‘off ’) has been considered to be not compliant
with the intended use as reported in the device user
manual. Consequently, the study has been notified to
the Competent Authorities of all participating countries
which will receive a periodic report on the progress of
the study and immediate notification of any serious
adverse event observed by the investigators and re-
ported to the study sponsor. Recruitment will not start
in each participating country/study site until all necessary
Competent Authority and Ethics Committee approvals
have been obtained. Study-specific Patient Information
Sheets and Consent Forms have been prepared and are
reviewed by competent Ethics Committees. Finally, the
study progression is periodically reviewed by an independ-
ent Data Safety Monitoring Board (DSMB) which is
provided with regular biannual safety reports. According to
the DSMB charter, meetings for reviewing the study status
and adverse event recurrences, and for providing recom-
mendations, including study termination or suspension,
take place in the following situations: (1) regularly every 6
months, (2) immediately (within 30 days) upon notification
of a death in any study arm (further meetings related to a
patient’s death may be scheduled to review documents
subsequently made available), (3) unscheduled meetings
may be requested by the sponsor in case the observed
adverse event rate indicates an unexpected accumulation of
events or is otherwise suspicious and (4) at the planned
interim analyses as soon as the relative report is made
available (within 30 days). Safety reports and DSMB
meeting minutes are distributed to the involved Competent
Authorities, Ethics Committees and investigators.
Inclusion/exclusion criteria
Patients may participate to the study after providing written
consent and provided that they fulfill the inclusion/exclu-
sion criteria listed in Table 1. Inclusion criteria basically re-
flect the current class IIb indication for cardiac pacing,
selecting subjects aged 40 years or older with significantly
impaired quality of life due to unpredictable and frequent
syncopal recurrences (at least two occurrences in the last
year), and a type 2B cardio-inhibitory response (according
to the VASIS classification) to the baseline TT performed
prior to enrollment. All competing causes of syncope, in-
cluding carotid sinus hypersensitivity, must be excluded.
In order to minimize any additional study-related risk,
only investigators who explicitly state that they normally
consider cardiac pacing among therapy options for
eligible patients in their ordinary medical practice may
participate.
Implantation, randomization and follow-up
After the written informed consent and enrollment, patients
undergo dual-chamber pacemaker (DDD) implantation ac-
cording to standard procedures. Before being discharged,
patients will be randomized to the active group (DDD
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pacing ‘on’) or to placebo (pacing ‘off ’). The randomization
ratio is 1:1 with a centralized non-stratified block procedure.
Block size will vary from 2 to 4 and investigators are not
aware of randomization block sizes at any time.
Randomization is communicated with an online procedure.
After entering patient enrollment data in the web-based
electronic data capture system used for data collection, the
randomization is automatically displayed by the system to
the investigator who will proceed to program the implanted
device accordingly before hospital discharge. The investiga-
tor and site study staff are not blinded to the assigned treat-
ment and will not communicate the active pacemaker mode
to the patient. Deviation will be reported.
After implantation, patients are visited in out-patient
clinic at 12 and 24 months unless earlier termination
and optionally monitored remotely with the home moni-
toring system [10]. At 1 month an optional additional
in-person visit may be performed in order to repeat the
TT, according to the Italian protocol [11]: electrocardio-
gram and systolic/diastolic blood pressure will be con-
tinuously monitored and recorded using an external
device; after 10 min of supine rest, the patient is tilted to
60°–70° using an electronically operated tilt-table with a
foot-board. If syncope does not occur after 20 min, 300
mcg of nitroglycerin will be administered, and the test
continued for a further 20 min or until syncopal occur-
rence. Device programming assigned by randomization
will not be changed during the 1-month TT.
Regular study termination is at 24-month follow-up. How-
ever, patients immediately terminate study participation at
the first adjudicated primary endpoint (syncope). Further
reasons for early termination are consent withdrawal or
death. At study termination, devices must be reprogrammed
in all the patients enrolled in the placebo arm.
All data are collected with electronic Case Report Forms
on a web-based data capture system (iMedNet, MedNet
Solution, Minnetonka, MN, USA). Data undergo automatic
range and plausibility checks at entering and are further
monitored with a percentage-based verification of source
documents escalating in case of poor study compliance.
The study flowchart is shown in (Fig. 1) and assess-
ment, tests and interventions are shown in (Fig 2).
Endpoint assessment and blinding
According to the 2009 ESC guidelines, the primary endpoint
of the study is the time to the first post-randomization re-
currence of a syncopal episode, defined as a transient
complete loss of consciousness characterized by rapid onset,
short duration and spontaneous complete recovery [11].
Similarly, pre-syncope is a secondary study endpoint, de-
fined as signs and symptoms recognized by the patients as
premonitory of imminent syncope but not followed by
syncope. Primary and secondary endpoints are based on
patients’ questionnaire responses and are reviewed by an in-
dependent Adjudication Committee whose members are
blinded to randomization.
A special method for blinding is implemented in the
study design. Patient- and outcome-assessor-blinding is
ensured by the patient and the independent Adjudication
Committee, both being blinded to random assignments.
Patients will be blinded to the treatment assignment until
the end of the study or the first endpoint event. Despite
investigators not being blinded to randomization, they will
not be involved in the collection and assessment process
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients affected by clinical diagnosis of reflex syncope who meet all the
following criteria:
1- Age ≥40 years
2- Significant limitation of social and working life due to unpredictable
frequent syncopal recurrences (≥2 within the last year)
3- Type 2B cardio-inhibitory response to the TT (according to the VASIS
classification)
4- Alternative therapies have failed or were not feasible
5- Exclusion of other possible competitive causes of syncope
1- Any other indication to pacemaker, implantable defibrillator or
cardiac resynchronization therapy, according to current guidelines
2- Any cardiac dysfunctions possibly leading to loss of consciousness:
Overt heart failure
Left ventricular ejection fraction (LVEF) <40% (echo-assessed within
3 months prior to study participation)
Myocardial infarction Diagnosis of hypertrophic or dilated cardiomyopathy
Clinically significant valvular disease
Sinus bradycardia <50 bpm or sinoatrial block
Mobitz I second-degree atrioventricular block
Mobitz II second or third-degree atrioventricular block
Bundle-branch block




Arrhythmogenic right ventricular cardiomyopathy
3- Symptomatic orthostatic hypotension diagnosed by standing BP
measurement
4- Non-syncopal loss of consciousness (e.g., epilepsy, psychiatric, metabolic,
drop-attack, cerebral transient ischemic attack, intoxication, cataplexy)
5- Symptomatic cardio-inhibitory carotid sinus hypersensitivity
BP blood pressure, TT Tilt-Table test, VASIS VAsovagal Syncope International Study
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of study endpoints. This should also facilitate pacemaker
reprogramming in case of emergency as no predefined in-
vestigator unblinding procedures are required. Indeed,
syncope and pre-syncope study endpoints will be collected
by means of a specifically designed self-administered pa-
tient questionnaire. Responses to the questionnaire will
determine whether or not the event description and the
associated symptoms are consistent with a syncopal and
pre-syncopal recurrence. Patients will fill in the question-
naires by themselves at home; personnel of a contract re-
search organization (CRO) will collect questionnaires;
members of the event Adjudication Committee adjudicate
questionnaires as study endpoints. Patients, CRO staff,
Adjudication Committee members will be all blinded to
randomization.
In more detail, investigators are first recommended to
administer a test questionnaire at enrollment to familiarize
patients with the questions, provide all necessary
explanations of ultimate meaning of terms and questions,
and to reconfirm concordance with history taking. Further
blank questionnaires are provided to patients at post-
implantation hospital discharge. Shipping envelopes for the
CRO office are pre-addressed. At enrollment, participating
subjects are instructed to fill in and mail the questionnaires
to the CRO. Patients are asked to complete one question-
naire at home by themselves for each single experienced
syncopal or pre-syncopal event. Soon after the first synco-
pal event or at least every 3 months from enrollment, pa-
tients are asked to mail the collected questionnaires to the
CRO using the pre-addressed envelopes provided at enroll-
ment. Filled-in questionnaires are processed by blinded
CRO staff, who will enter patients’ answers and upload the
original paper sheets on an online electronic data capture
system. The three-member event Adjudication Committee
blinded to randomization will adjudicate questionnaires
within 30 days from the upload following a predefined
charter to classify self-reported events as syncope, pre-
syncope or no event (Additional file 2). CRO personnel
will also monitor the timing of questionnaire flow and
inform investigators about the occurrence of a syncopal
or pre-syncopal event. In the meantime, investigators are
asked to follow their normal practice taking appropriate
medical actions, including pacemaker reprogramming if
deemed necessary.
Questionnaire validation
A 12-item questionnaire (Table 2) was developed to dis-
tinguish between complete transient loss of consciousness
(i.e., syncope) and pre-syncope or other minor symptoms
and, additionally, to provide a standardized categorical de-
scription of the clinical presentation of syncope including
duration, reproducibility with previous episodes, presence
of prodromes, presence of witnesses, context, and conse-
quences of the episode. In all previous studies, as well as
in normal medical practice, syncopal recurrences are eval-
uated by physicians who generally base their assessment
on what patients report. As in this study (pre-)syncopal
events are reported with self-administered patient
questionnaires, we preliminarily estimated consistency
between syncopal/pre-syncopal assessments based on
questionnaires and face-to-face interviews.
Before the BIOSync study started, the questionnaire was
validated in 77 consecutive independent (i.e., not recruited
in the BIOSync study) patients referred to three tertiary
Fig. 1 Study flowchart. ECG electrocardiogram, DDD-CLS dual-chamber pacing with Closed Loop Stimulation, IPG pacemaker, ODO pacing ‘off’,
R randomization, TT Tilt-Table test
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syncope clinics (Lavagna, Bolzano and Empoli). These pa-
tients were asked to fill the questionnaire before their visit
in a separate room without any help from the hospital staff.
Subsequently, the attending physician interviewed the pa-
tient and independently filled the same questionnaire while
being unaware of the responses reported by the patient in
their questionnaire. Patients’ responses were considered to
be the input data and were checked against physician evalu-
ation. The median age of the patients was 68 years (inter-
quartile range 47–79), 50% of patients were male; they had
had a median of two episodes of transient loss of conscious-
ness (interquartile range 2–4); 50% were taking pharmaco-
logical therapy and 29% had some cardiac abnormality; the
final diagnosis of syncope was vasovagal in 57%, orthostatic
hypotension in 7%, cardiac in 3% and suspected cardiac
cause needing further evaluation in 33%. The results were:
(1) all patients were able to complete the questionnaire, (2)
physicians and patients agreed in their syncope/pre-syn-
cope diagnosis in 74 (56 syncopal episodes, 18 pre-syncopal
episodes) of 77 cases (96.1% of patients/physicians agreed
with diagnosis, 95% confidence interval (CI), 0.86–0.99)
with a Cohen concordance kappa of 0.90 (p < 0.0001). Fur-
ther details are reported in the Table 3.
Device programming
The BIOSync study has been designed to test DDD
pacing against placebo (pacing ‘off ’), irrespective of any
specific pacing mode or algorithm, as there is no clear
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out*






























Fig. 2 Schedule of enrolment, interventions, and assessments. *Patients will terminate their participation at the 24-month in-hospital follow-up or
at the assessment of a primary endpoint event occurrence, whichever comes first. **Optional in-hospital visit. DDD-CLS dual-chamber pacing with
Closed Loop Stimulation, ODO 'sensing only' mode, pacing ‘off’
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Table 2 Self-administered patient questionnaire
1) Did you faint (losing consciousness partially or completely)? ◯0 No
◯1 Yes - date: (dd-mm-yyyy) __ __ - __ __ - __ __ __ __
2) If ‘yes’, ◯0 You completely lost consciousness? ◯1 You recognized having the premonitory
symptoms of imminent loss of consciousness but they were not followed by
complete loss of consciousness, i.e., pre-syncope?
If ‘yes’ only:
3) Was the episode characterized by a rapid onset, short
duration and spontaneous complete recovery?
◯0 No ◯1 Yes
4) Have you realized that the episode was similar to those
that you had before the pacemaker implantation?
◯0 No ◯1 Yes
5) Have you had time to stop and lie/sit down? ◯0 No ◯1 Yes
6) Was the event witnessed by other people? ◯0 No ◯1 Yes
7) Where did the event occur? ◯0 At home
◯1 Away from home
8) What were you doing immediately before the event? ◯0 I was standing
◯1 I was sitting
◯2 I was lying
◯3 I had just stood up
9) Please describe the situation: _____________________________________
_____________________________________
_____________________________________
10) Have you been injured due to the event? ◯0 No ◯1 Yes
11) Did you go to the emergency room due to the injuries? ◯0 No ◯1 Yes
12) Were you hospitalized due to the injuries? ◯0 No ◯1 Yes









1–2. Syncope/pre-syncope 59/18 56/21 0.90 (0.11) <0.0001
3. Onset, duration, recovery 62/9 61/10 0.21 (0.12) 0.04
4. Similar to previous episodes 50/16 50/16 0.67 (0.12) < 0.0001
5. Time to stop and lie/sit down 38/33 42/29 0.67 (0.12) < 0.0001
Context
6. Presence of witnesses 46/28 50/24 0.70 (0.11) < 0.0001
7. Location 52/25 52/24 0.69 (0.11) < 0.0001
8. Contemporary actions/position
Standing 40 32
Sitting 21 24 0.58 < 0.0001
Lying 2 4
Standing up 7 6
Sequelae
10. Injuries 29/40 31/38 0.88 (0.12) < 0.0001
11. Access to emergency room 26/43 26/43 1.00 (0.12) < 0.0001
12. Hospitalization 13/57 14/56 0.68 (0.12) < 0.0001
aKappa agreement in the range 0.21–0.40 is considered fair, 0.41–0.60 moderate, 0.61–0.80 substantial, 0.81– 1.00 almost perfect
bZ statistic p values (Stata/SE 11.1, StataCorp LP, TX, USA)
SE = standard error
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evidence of additional related benefit so far. However,
for the sake of consistency, specific recommendations are
provided for device programming in the active group, in-
cluding an inotropic-sensor-based rate-responsive algo-
rithm (namely Closed Loop Stimulation [12]) as it has
shown to be potentially effective in preventing syncopal
recurrence in previous small randomized studies and
retrospective analyses [13–15].
Statistical consideration and analysis plan
Standard descriptive statistics will be calculated for all
patients and study outcome variables. Categorical data
will be summarized via distributions of absolute and
relative frequencies. For all relevant parameters 95% CIs
will be calculated.
For the analysis of the primary and secondary end-
points, Kaplan-Meier plots will be generated and the
estimated survival functions of the study groups will
be tested with the two-sided log-rank test. Depend-
ence of survival on major baseline predictors will be
studied with proportional hazard Cox models. Hazard
ratios and relative 95% CIs for each predictor will be
calculated, respectively. Data will be censored at the
date of last patient contact. Missing or spurious data
will be not substituted and all data – as far as cor-
rectly measured – will be analyzed. The intention-to-
treat principle will be applied.
The study sample size calculation was based on the least
expected relative difference in the 2-year incidence of syn-
copal recurrences as compared with placebo (pacing ‘off ’).
The 2-year incidence of the primary endpoint in the
control group has been assumed to be equal to the inci-
dence observed in the control arm of the ISSUE-3 trial
[6]: this was reported to be as high as 57%. The BIOSync
study was designed to detect a 40% relative reduction in
the 2-year incidence of syncopal recurrences (from 57%
to 34%) with statistical type I and type II errors of 0.05
(bilateral) and 0.20 (80% power), respectively, using a
log-rank test. Further assumptions were exponential
distribution of time to first recurrence, 2- and 4-year
accrual time and study duration, respectively, 1:1
randomization ratio, and 10% loss in both arms.
With these assumptions, a sample size of 62 patients
per study arm is required, to be further increased by 2%
due to the slight power loss induced by the planned in-
terim analyses. In summary, 128 subjects (64 per study
arm) were deemed necessary to reach the study primary
objective with the required power.
Sixty-two primary endpoint events are necessary to
reach the primary study objective. Interim analyses will
be performed when 40% and 70% of the required pri-
mary endpoint events (25 and 43 events, respectively)
will be collected.
In order to keep the overall type I error at the 0.05
level, two-sided, symmetric O’Brien-Fleming boundaries
generated with the Lan-DeMets spending function ap-
proach to group-sequential testing have been assumed
as early stopping rules for efficacy (absolute Z values at
interim and final analyses, 3.36, 2.44, 2.00).
Sample size was estimated twice by two biostatisticians
independently of each other. Calculations were first per-
formed with StudySize 2.0.4 software (CREOSTAT HB,
V.Frolunda, Sweden) and checked with Stata/SE 11.1
software (StataCorp LP, TX, USA). O’Brien-Fleming
boundaries for group-sequential testing were generated
with R Software (version 3.1.0 2014-04-10).
The SPIRIT 2013 Checklist specific for the BIOSync
study is reported in the Additional file 3.
Discussion
The BIOSync study is expected to answer several ques-
tions concerning the real benefit of cardiac pacing and the
effectiveness of the TT as a screening tool, while introdu-
cing a new methodological approach which should ensure
complete blinding in the endpoint assessment.
Benefit of pacing and patient selection
The current class IIb indication for cardiac pacing in pa-
tients older than 40 years with an asystolic response to
the TT reflects current divergent opinion within the sci-
entific community due to lack of consistency of studies
on which the indication relies:
 The SYDIT [2] and VASIS PM [3] trials selected
patients with positive cardio-inhibitory (mostly, but
not exclusively asystolic) response during the TT.
Two-year results were in favor of pacing with a
significant reduction of syncopal recurrences in the
pacemaker arm. However, the SYDIT study was
terminated early and both SYDIT and VASIS studies
were open-label. Studies on syncopal recurrences
may be particularly prone to potential bias deriving
from a lack of blinding
 The VPS II [4] and the SYNPACE [5] studies, which
included younger patients with both cardio- and
non-cardio-inhibitory responses to the TT, failed to
demonstrate significant superiority of pacing
Also, data from recent studies gave contrasting results.
The ISSUE-3 [6] trial definitively showed superiority of
pacing against placebo in reflex syncope patients with
clinical asystole documented during long-term cardiac
monitoring, irrespective of the TT response. However, in
the subgroup of the VASIS IIB response to the TT
(asystole), syncope still recurred after cardiac pacing in
35% (95% CI, 13–75) of patients at 12 months [16].
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The latter result was actually obtained in a very small
subgroup. More recently, in the larger VASIS IIB patient
cohort of the SUP 2 study [8], much better outcomes
were observed, with a syncopal recurrence rate well below
the range of confidence of the ISSUE-3 trial results: 3%
(95% CI, 0–6) at 12 months and 17% (95% CI, 3–31) at 21
months. These data have indicated that cardiac pacing
was able to approximately halve the recurrence rate as
compared with non-paced patients. Thus, the issue of
pacing in VASIS IIB patients is far from being clarified.
Such an uncertainty compellingly requires a better un-
derstanding. Nowadays, patients either receive a pace-
maker or not according to physicians’ individual opinion
unsupported by any conclusive evidence. Although the
ODO mode programming after pacemaker implantation
inevitably makes patient recruitment difficult and may
also raise ethical concerns at a first glance, controlling
placebo effect is crucial in a syndrome with strong and
uncontrolled psychological implications. Inherent risks
are acceptably low. In fact, other studies previously con-
ducted with a similar design never reported any syncope-
related death or permanent injuries [4–6]. However, study
termination after the first syncopal recurrence (also
allowed prior to adjudication), interim analysis design for
early termination for efficacy and safety, independent
DSMB, are among the main measures taken to mitigate
risks as reported in the risk analysis document approved
by the involved Competent Authorities. In order to ensure
adequate recruitment, selection of participating sites is
based on documented experience of reflex syncope and
cardiac pacing as well as on the number of yearly per-
formed TTs. As about 17% of TT responses are expected
to be VASIS IIB type [9], recruiting 30 sites routinely per-
forming at least 100 TTs should ensure completion of the
enrolling phase in about 2 years, assuming that at least
two eligible subjects per year will consent to participate.
Pacing mode selection
The main objective of the BIOSync study is to evaluate
the effect of DDD pacing against placebo irrespective of
specific pacing modes or algorithms available in modern
devices. Therefore, the study will not provide informa-
tion about any potential additional benefit expected
from a particular choice of the pacing mode, nor do the
authors believe that this may be critical for the study
outcomes. Nevertheless, we selected the Closed Loop
Stimulation algorithm in the active group as few small
studies have reported that this particular pacing mode
may provide additional benefit [13–15]. The system in-
directly monitors cardiac contractility, adapting pacing
rate correspondingly [12]. It has been hypothesized that
the detection of an increase in contractility in an earlier
stage of a vasovagal syncope could allow the system to
activate atrioventricular pacing that may anticipate
withdrawal of sympathetic tone and counterbalance
vagal tone reaction. The TT repetition scheduled at 1
month during the study should verify this theory and in-
directly investigate whether or not contractility change is
involved in the mechanism triggering loss of conscious-
ness, at least as a response to the TT-induced orthostatic
stress.
Self-administered patient questionnaire
Finally, we would emphasize the introduction of a new
method to assess the primary and secondary study
endpoints in studies on reflex syncope, ensuring inde-
pendent event adjudication. The process is based on
self-administered questionnaires which are periodic-
ally collected by an external agency and forwarded to
an independent three-member committee.
Obtaining reliable follow-up data on soft endpoints,
such as syncopal recurrence, is a major challenge in all
clinical trials. It is well known that syncopal recurrence
rate is not constant in time, but rather fluctuates over
time, peaking at the time of evaluation and decreasing
spontaneously during follow-up (the so called “regression-
to-the-mean effect” [17]). Time to recurrence is largely
unpredictable and many patients do not have true synco-
pal relapses during even a long follow-up period. When a
real double-blinding is difficult to achieve, such as, for
example, in trials on medical devices, some “physicians’
expectation effect” cannot be excluded [18]. The difficulty
of obtaining a reliable history is well known, especially
if it is taken by non-experts [19]. As consequence, pre-
syncope or other minor symptoms might be considered
as appealing surrogate endpoints or, alternatively, a true
syncopal episode might be underestimated as a non-
syncopal episode. In order to overcome such potential
biases, a possible solution is to let syncope endpoint be
assessed by the patients themselves who will be blinded
to the treatment assignment. The approach is in line
with the increasingly acknowledged viewpoint that patient-
reported outcomes, especially related to symptoms, health-
related quality of life, or patient-perceived health status, are
powerful tools in clinical research [20, 21]. With this in
mind, we have developed a simple questionnaire which
could be self-administrated in patients and definitively shel-
tered from physician influence. Although our approach
may still be prone to unintended randomization disclosure
to patients, it definitely excludes investigator expectation ef-
fects from endpoint assessment.
With a preliminary validation on 77 syncope individ-
uals, we could confirm that event adjudication based on
patient questionnaires is almost equivalent to physician
assessment based on direct patient interviews; therefore,
it can be used for evaluation of the outcome of the
BIOSync study as well as in other syncope trials. The pa-
tient self-assessment of outcome in clinical trials offers
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important advantages over investigator assessment because
it avoids the potential biases given by the expectation effect
and the difficulty to reliably ensure double-blinding. In the
BIOSync study, questionnaires are filled in at home by pa-
tients and mailed directly to the study data management
system avoiding the potential contamination of the visit in
the syncope clinic.
It is worth noting that patient-physician agreement of
the questionnaire has been tested in the original language
version only. Unfortunately, cross-cultural validation into
other languages, which is arguably an important issue, has
not yet been performed. However, the questionnaire
development process reflected several recommendations
of the Test Development and Adaptation Guidelines set
forth by the International Test Commission [22]. The
results of the study may be used to provide evidence of
the equivalence of questions for all intended populations.
Finally, it is intrinsically simple, basically addressing the
two main concepts of syncope and pre-syncope which pa-
tients have repeatedly experienced per selection criteria
and should be further explained by qualified investigators
prior to study participation. The remaining items trivially
address the context of event recurrence with terms and
tools which are considered appropriate in all the popula-
tion involved in the study.
If the implementation in the BIOSync study proves
successful, we believe that the patients’ self-assessment
syncope questionnaire could become a standard tool for
the assessment of syncope endpoints in syncope trials,
after proper cross-cultural validation.
In conclusion, the BIOSync study is a randomized clin-
ical trial designed to reliably assess the benefit of pacing
against placebo in patients aged 40 years and older with
frequent syncopal recurrences, with a cardio-inhibitory
response to TT after all competing causes have been
excluded. The study will also provide important information
about the efficiency of the TT in appropriately selecting
reflex syncope patients for cardiac pacing.
Trial status
Thirty sites are planned to be recruited in Italy, France,
Spain, Portugal, Netherlands and Canada, where approvals
from Competent Authority and Ethics Committees have
been obtained or application is currently under preparation.
Recruitment has started only in the study sites where all
necessary Competent Authority and Ethics Committee
approvals have been obtained. The enrollment started in
October 2015 and will last approximately 2 years.
Amendment history
The clinical investigation plan has been amended twice
since its first application. A first non-substantial amend-
ment was triggered by a specific Competent Authority
request and consisted of a slight rewording of the
second inclusion criterion in order to avoid confusion
and clarify that syncopal recurrence in patients’ histories
should be both frequent and unpredictable. The second
amendment was classified as substantial and was due to
the recently issued revision 3 of MEDDEV 2.7/3 con-
cerning serious adverse event classification and report-
ing. Affected sections of the clinical investigation plan
were changed accordingly. Communication and/or writ-
ten approval of the involved Ethics Committees and
Competent Authorities are requested before amendment
application.
Additional files
Additional file 1: List of sites, Competent Authority (CA) and Ethics
Committee (EC) approvals. The file reports the list of qualified sites and
their CA and EC approvals status. (PDF 122 kb)
Additional file 2: Charter for patient questionnaire collection and
adjudication, version 1.0, 17 Nov 2015. This charter describes the
procedures for patient questionnaire collection and adjudication, and the
details of the Adjudication Committee. (PDF 530 kb)
Additional file 3: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 130 kb)
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